7.58
price up icon6.61%   0.47
pre-market  Pre-market:  7.69   0.11   +1.45%
loading
Tempest Therapeutics Inc stock is traded at $7.58, with a volume of 67,193. It is up +6.61% in the last 24 hours and down -29.05% over the past month. Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
See More
Previous Close:
$7.11
Open:
$7.14
24h Volume:
67,193
Relative Volume:
1.14
Market Cap:
$26.26M
Revenue:
-
Net Income/Loss:
$-31.11M
P/E Ratio:
-4.9542
EPS:
-1.53
Net Cash Flow:
$-28.18M
1W Performance:
+1.61%
1M Performance:
-29.05%
6M Performance:
-44.47%
1Y Performance:
-82.00%
1-Day Range:
Value
$7.14
$7.80
1-Week Range:
Value
$7.00
$7.80
52-Week Range:
Value
$5.3495
$49.27

Tempest Therapeutics Inc Stock (TPST) Company Profile

Name
Name
Tempest Therapeutics Inc
Name
Phone
415-798-8589
Name
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Name
Employee
25
Name
Twitter
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
TPST's Discussions on Twitter

Compare TPST with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TPST
Tempest Therapeutics Inc
7.58 26.26M 0 -31.11M -28.18M -1.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.47 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.49 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.87 36.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.75 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.77 25.74B 3.81B -644.79M -669.77M -6.24

Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-10-25 Downgrade H.C. Wainwright Buy → Neutral
Apr-10-25 Downgrade Scotiabank Sector Outperform → Sector Perform
Mar-14-24 Initiated Scotiabank Sector Outperform
Feb-08-24 Initiated Jefferies Buy

Tempest Therapeutics Inc Stock (TPST) Latest News

pulisher
Apr 22, 2025

Tempest Therapeutics - The Pharma Letter

Apr 22, 2025
pulisher
Apr 21, 2025

Tempest Therapeutics stock rises on FDA Orphan Drug Designation By Investing.com - Investing.com Nigeria

Apr 21, 2025
pulisher
Apr 21, 2025

Tempest Therapeutics stock rises on FDA Orphan Drug Designation - Investing.com Australia

Apr 21, 2025
pulisher
Apr 21, 2025

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - GlobeNewswire

Apr 21, 2025
pulisher
Apr 21, 2025

FDA Awards Rare Disease Drug Status to Tempest's Novel FAP Treatment: Phase 2 Trial Coming in 2025 - Stock Titan

Apr 21, 2025
pulisher
Apr 13, 2025

TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up - MSN

Apr 13, 2025
pulisher
Apr 12, 2025

Scotiabank Reaffirms “Sector Perform” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World

Apr 12, 2025
pulisher
Apr 12, 2025

HC Wainwright Reaffirms Neutral Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger - Asianet Newsable

Apr 11, 2025
pulisher
Apr 10, 2025

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

Tempest seeks strategic alternatives as cash runs out for Phase 3 trial - BioPharma Dive

Apr 10, 2025
pulisher
Apr 10, 2025

Tempest to explore alternatives to advance promising pipeline - The Pharma Letter

Apr 10, 2025
pulisher
Apr 10, 2025

HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

Tempest hits funding block for Phase III liver cancer drug-in-waiting - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Tempest seeks strategic alternatives to fund Phase 3 liver cancer trial - Endpoints News

Apr 10, 2025
pulisher
Apr 09, 2025

Tempest Therapeutics evaluates strategic options amid advancements By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 09, 2025

Tempest Therapeutics Terminates Loan Agreement with Oxford - TipRanks

Apr 09, 2025
pulisher
Apr 09, 2025

Tempest Therapeutics Mulls Alternatives to Advance Cancer Treatment Programs - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Tempest Therapeutics Seeks Partner as It Explores Strategic Alternatives - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Tempest Therapeutics evaluates strategic options amid advancements - Investing.com

Apr 09, 2025
pulisher
Apr 09, 2025

Tempest Announces Plan to Explore Strategic Alternatives to - GlobeNewswire

Apr 09, 2025
pulisher
Apr 07, 2025

Tempest Therapeutics announces 1-for-13 reverse stock split - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

Tempest Therapeutics announces 1-for-13 reverse stock split By Investing.com - Investing.com Canada

Apr 07, 2025
pulisher
Apr 07, 2025

Tempest Therapeutics Announced 1-For-13 Reverse Stock Split - MarketScreener

Apr 07, 2025
pulisher
Apr 05, 2025

TPST stock touches 52-week low at $0.69 amid market challenges - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

TPST stock touches 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 03, 2025

Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Update - Defense World

Apr 03, 2025
pulisher
Apr 02, 2025

Virtu Financial LLC Purchases Shares of 43,105 Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Estimate for TPST Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

FY2028 Earnings Estimate for TPST Issued By William Blair - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

HC Wainwright Has Lowered Expectations for Tempest Therapeutics (NASDAQ:TPST) Stock Price - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Scotiabank Has Lowered Expectations for Tempest Therapeutics (NASDAQ:TPST) Stock Price - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Scotiabank Lowers Tempest Therapeutics (NASDAQ:TPST) Price Target to $7.00 - Armenian Reporter

Mar 30, 2025
pulisher
Mar 29, 2025

Tempest Therapeutics (NASDAQ:TPST) Given New $16.00 Price Target at HC Wainwright - The AM Reporter

Mar 29, 2025
pulisher
Mar 28, 2025

Tempest Therapeutics Advances Cancer Therapies Amid Financial Challenges - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

H.C. Wainwright cuts Tempest Therapeutics stock target to $16 By Investing.com - Investing.com UK

Mar 28, 2025
pulisher
Mar 27, 2025

Tempest Therapeutics Inc. (TPST) reports earnings - Quartz

Mar 27, 2025
pulisher
Mar 27, 2025

Why Super Micro Computer Stock Was Sliding This Week - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

Tempest Reports Year End 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Tempest's Cancer Drug Shows 6-Month Survival Gain, Lands Major Roche Partnership - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Tempest Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView

Mar 26, 2025
pulisher
Mar 25, 2025

Tempest Announces Amezalpat Poster Presentation at the 2025 - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting - Yahoo

Mar 25, 2025
pulisher
Mar 25, 2025

Breakthrough Cancer Drug Data Reveals New Immune Response Findings at AACR 2025 - Stock Titan

Mar 25, 2025
pulisher
Mar 15, 2025

Layoff Tracker: Tempest Axes 80% of Workforce - BioSpace

Mar 15, 2025
pulisher
Mar 13, 2025

Tempest Therapeutics advances Phase 2 trial for cancer prevention By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

FDA Study May Proceed Notice Received for Phase 2 Trial of - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Tempest Therapeutics Says Familial Adenomatous Polyposis Trial Gets US FDA 'Study May Proceed' Notice - Marketscreener.com

Mar 13, 2025

Tempest Therapeutics Inc Stock (TPST) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.27
price up icon 1.00%
$71.24
price up icon 2.49%
$32.19
price up icon 0.00%
$27.35
price up icon 8.45%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.27%
Cap:     |  Volume (24h):